Patient Assistance Programs: A Source of Real-World Data?

https://admin.biospace.com/getasset/bab4ecbd-e7cb-449f-9fd8-e54f45f12c63/?&Test=Test

Pictured: Illustration of pie chart composed of people/iStock, arthobbit

Early last month, Kite Pharma, a subsidiary of Gilead Sciences, reported the results of an analysis that pooled data from clinical trials on the lymphoma drug Yescarta and patient data scraped from the patient support site Kite Konnect. The analysis found that the CAR T cell therapy was more effective as a second line of treatment than as a third-line treatment for relapsed/refractory large B cell lymphoma.

Kite’s use of data from a patient support program highlights the potential use of these programs as a source of real-world evidence about a product—but just how common this practice is remains unclear. Drugmakers contacted by BioSpace, including Eli Lilly, Biogen, Kite Pharma and GSK, declined to discuss whether they collect patient outcome data as part of patient assistance programs and if so, how it is used.


Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks